Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-242 in Acute Alcoholic Hepatitis and Acute-on-Chronic Liver Failure
NCT04620148Phase 2Terminated
- Sponsor
- Akaza Bioscience Ltd.
- Start
- Nov 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of resatorvid in acute-on-chronic liver failure (ACLF), alcoholic hepatitis (AH), sponsored by Akaza Bioscience Ltd.. Started Nov 2020; status: terminated.
02
Drugs
resatorvid
03
Conditions
acute-on-chronic liver failure (ACLF)alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT04620148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620148.